Brief: Chimerix Announces FDA Acceptance And Priority Review Of New Drug Application For Dordaviprone

Chimerix

18/02/2025 12:11

Feb 18 (Reuters) - Chimerix Inc  CMRX.O :
    * CHIMERIX ANNOUNCES FDA ACCEPTANCE AND PRIORITY REVIEW OF
NEW
DRUG APPLICATION FOR DORDAVIPRONE AS TREATMENT FOR RECURRENT H3
K27M-MUTANT DIFFUSE GLIOMA
    * CHIMERIX INC - FDA GRANTS PRIORITY REVIEW TO CHIMERIX'S
DORDAVIPRONE, PDUFA DATE AUGUST 18, 2025
    * CHIMERIX INC - NO ADVISORY COMMITTEE MEETING PLANNED FOR
CHIMERIX'S DORDAVIPRONE NDA

Source text:  ID:nGNX2LbQJt 
Further company coverage:  CMRX.O 

 ((Reuters.Briefs@thomsonreuters.com;))